Renal cell carcinoma of the kidney transplant : The French guidelines from CTAFU
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
OBJECTIVE: To propose recommendations for the management of renal cell carcinomas (RCC) of the renal transplant.
METHOD: Following a systematic approach, a review of the literature (Medline) was conducted by the CTAFU to evaluate prevalence, diagnosis and management of RCC arousing in the renal transplant. References were assessed according to a predefined process to propose recommendations with levels of evidence.
RESULTS: Renal cell carcinomas of the renal transplant affect approximately 0.2% of recipients. Mostly asymptomatic, these tumors are mainly diagnosed on a routine imaging of the renal transplant. Predominant pathology is clear cell carcinomas but papillary carcinomas are more frequent than in general population (up to 40-50%). RCC of the renal transplant is often localized, of low stage and low grade. According to tumor characteristics and renal function, preferred treatment is radical (transplantectomy) or nephron sparing through partial nephrectomy (open or minimally invasive approach) or thermoablation after percutaneous biopsy. Although no robust data support a switch of immunosuppressive regimen, some authors suggest to favor the use of mTOR inhibitors. CTAFU does not recommend a mandatory waiting time after transplantectomy for RCC in candidates for a subsequent renal tranplantation when tumor stage<T3 and low ISUP grade.
CONCLUSION: These French recommendations should contribute to improving the oncological and functional prognosis of renal transplant recipients by improving the management of RCC of the renal transplant.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 31(2021), 1 vom: 11. Jan., Seite 24-30 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Recommandations françaises du Comité de transplantation de l’association française d’urologie (CTAFU) : Carcinome à cellules rénales du transplant rénal |
|---|
| Beteiligte Personen: |
Tillou, X [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carcinome à cellules rénales |
|---|
| Anmerkungen: |
Date Completed 02.09.2021 Date Revised 02.09.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.purol.2020.04.029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319872580 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319872580 | ||
| 003 | DE-627 | ||
| 005 | 20231225172358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.purol.2020.04.029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1066.xml |
| 035 | |a (DE-627)NLM319872580 | ||
| 035 | |a (NLM)33423743 | ||
| 035 | |a (PII)S1166-7087(20)30684-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Tillou, X |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Renal cell carcinoma of the kidney transplant |b The French guidelines from CTAFU |
| 246 | 3 | 3 | |a Recommandations françaises du Comité de transplantation de l’association française d’urologie (CTAFU) : Carcinome à cellules rénales du transplant rénal |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.09.2021 | ||
| 500 | |a Date Revised 02.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVE: To propose recommendations for the management of renal cell carcinomas (RCC) of the renal transplant | ||
| 520 | |a METHOD: Following a systematic approach, a review of the literature (Medline) was conducted by the CTAFU to evaluate prevalence, diagnosis and management of RCC arousing in the renal transplant. References were assessed according to a predefined process to propose recommendations with levels of evidence | ||
| 520 | |a RESULTS: Renal cell carcinomas of the renal transplant affect approximately 0.2% of recipients. Mostly asymptomatic, these tumors are mainly diagnosed on a routine imaging of the renal transplant. Predominant pathology is clear cell carcinomas but papillary carcinomas are more frequent than in general population (up to 40-50%). RCC of the renal transplant is often localized, of low stage and low grade. According to tumor characteristics and renal function, preferred treatment is radical (transplantectomy) or nephron sparing through partial nephrectomy (open or minimally invasive approach) or thermoablation after percutaneous biopsy. Although no robust data support a switch of immunosuppressive regimen, some authors suggest to favor the use of mTOR inhibitors. CTAFU does not recommend a mandatory waiting time after transplantectomy for RCC in candidates for a subsequent renal tranplantation when tumor stage<T3 and low ISUP grade | ||
| 520 | |a CONCLUSION: These French recommendations should contribute to improving the oncological and functional prognosis of renal transplant recipients by improving the management of RCC of the renal transplant | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Carcinome à cellules rénales | |
| 650 | 4 | |a Kidney transplant | |
| 650 | 4 | |a Renal cell carcinoma | |
| 650 | 4 | |a Renal transplantation | |
| 650 | 4 | |a Transplant rénal | |
| 650 | 4 | |a Transplantation rénale | |
| 700 | 1 | |a Doerfler, A |e verfasserin |4 aut | |
| 700 | 1 | |a Szabla, N |e verfasserin |4 aut | |
| 700 | 1 | |a Verhoest, G |e verfasserin |4 aut | |
| 700 | 1 | |a Defortescu, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bessede, T |e verfasserin |4 aut | |
| 700 | 1 | |a Prudhomme, T |e verfasserin |4 aut | |
| 700 | 1 | |a Culty, T |e verfasserin |4 aut | |
| 700 | 1 | |a Bigot, P |e verfasserin |4 aut | |
| 700 | 1 | |a Bensalah, K |e verfasserin |4 aut | |
| 700 | 1 | |a Méjean, A |e verfasserin |4 aut | |
| 700 | 1 | |a Timsit, M-O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie |d 1997 |g 31(2021), 1 vom: 11. Jan., Seite 24-30 |w (DE-627)NLM012649481 |x 1166-7087 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:1 |g day:11 |g month:01 |g pages:24-30 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.purol.2020.04.029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 1 |b 11 |c 01 |h 24-30 | ||